2016 Q4 Our Commitment to Innovation: MiniMed 630G with SmartGuard Technology

Our Commitment to Innovation:
MiniMed® 630G with SmartGuard Technology


OUR COMMITMENT TO INNOVATION: MiniMed 630G with SmartGuard Technology

At Medtronic Diabetes, our main focus is bringing you the latest, most advanced technology so you can help your patients reach their goals. One example is the recent FDA-approved MiniMed® 630G system with SmartGuard™ technology, the newest member of the MiniMed family.

One of the most exciting features of the new MiniMed 630G system is the SmartGuard technology with Suspend on low, formerly known as Threshold Suspend. This feature uses data from the MiniMed 630G’s continuous glucose monitoring (CGM) device to not only alert the patient of low glucose values, but also automatically stop the insulin infusion from the pump when sensor glucose values reach a preset low limit.

Since its introduction, this feature has initiated approximately 1.5 million low-glucose suspension events in the U.S.* — 11 percent of which have lasted the full two hours. MiniMed’s SmartGuard technology helps to reduce the exposure to lows**—something we’re all concerned about for our patients. In addition, this technology takes us one step closer to an automatic or semi-automatic closed-loop insulin delivery device.

While technological advancement is an important initiative for Medtronic, we couldn’t do it without the help of diabetes educators like you. Your willingness to partner with Medtronic for the benefit of your patients is essential to achieving our shared goal of improving the lives of people living with diabetes through advanced diabetes technologies.

The MiniMed 630G system, along with other members of the MiniMed family of therapies, is a step toward our vision of working with our diabetes educator partners to transform diabetes care and provide patients with greater freedom and better health. These are exciting times and we look forward to continuing our partnership with you as new advancements continue to unfold.

Note: If you are interested in learning more about MiniMed 630G system with SmartGuard technology, please visit Healthcare Professional Website; Patient Website; and Loop Blog to hear what our patients have to say about the MiniMed 630G.

Thank you for all you do.

Francine Ratner Kaufman, MD, is Chief Medical Officer and VP of Global Clinical, Medical and Health Affairs at Medtronic Diabetes in Northridge, Calif.; a Distinguished Professor Emerita of Pediatrics and Communications at the Keck School of Medicine and the Annenberg School of Communications of the University of Southern California; and an attending physician at Children’s Hospital Los Angeles. Dr. Kaufman has published more than 220 peer-reviewed and invited publications and is the author of more than 40 books or book chapters. In 2012, she authored the Insulin Pump and Glucose Sensor Book for the American Diabetes Association (ADA) and edited the 6th edition of the ADA’s Medical Management of Type 1 Diabetes. In 2005, her book Diabesity was published by Bantam, and she recently released a novel entitled Rhythms. Dr. Kaufman has served as president of the American Diabetes Association (2002−03) and is a member of the Institute of Medicine.